Phase 2 Hypertension Trial, Recruiting NCT07553442 Sponsor: Alnylam Pharmaceuticals Condition: Hypertension
Back to Hypertension

Phase 2 Hypertension Trial, Recruiting

NCT07553442
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Part A:

  • Adults whose average seated blood pressure reading (the top number) is between 130 and 170 mmHg when measured in a clinic
  • People who are either not taking any blood pressure medication, or who have been on a steady dose of up to 2 blood pressure medications

Part B:

  • Adults whose average seated blood pressure reading (the top number) is between 140 and 170 mmHg when measured in a clinic
  • People who have stopped all blood pressure medications — except possibly a calcium channel blocker or a water tablet (diuretic) — for at least 3 weeks before joining

Who may not be able to join:

  • People whose high blood pressure is caused by another known medical condition, or who have high potassium levels in their blood (above 5 mmol/L)
  • People whose kidneys are not working well enough, based on a specific kidney function measurement falling below a certain level (confirm with trial site)

Additional note: There are other eligibility requirements beyond those listed here that the trial site will assess.


Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Medical Director, Alnylam Pharmaceuticals

Phone: 1-877-ALNYLAM

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Alnylam Pharmaceuticals
Registry
ClinicalTrials.gov
Start date
27 April 2026
Est. completion
1 April 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Part A: Percentage recovery from baseline in serum AGT; Part B: Percentage recovery from baseline in mean seated office SBP

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov